Entheon Biomedical (ENBI.X) AI Stock Analysis

• Market Cap: C$831.54K
• Dividend Yield: N/A
• Average Volume (3M): 4.05K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.28
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: CA
• Employees: 1
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.01
• Shares Outstanding: 13,858,926
• 10 Day Avg. Volume: 11,950
• 30 Day Avg. Volume: 4,053
• PEG Ratio: 0.09
• Price to Book (P/B): 3.72
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -3.83
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: C$0.06 ▼(-5.00% Downside)
• Action: Upgraded
• Date: 09/06/26

Positive Factors

Debt-Free Balance Sheet

A debt-free balance sheet reduces fixed financial obligations and interest pressure, giving the company more flexibility while it funds development. This does not remove operating risk, but it lowers solvency pressure compared with a similarly loss-making biotechnology company carrying significant borrowings.

Negative Factors

No Recent Revenue

Zero recent revenue shows that the company has not yet established a commercial income stream to support ongoing operations. Without recurring product or service revenue, progress remains dependent on advancing candidates successfully and securing additional funding over the next several quarters.

Entheon Biomedical Business Overview & Revenue Model

Company Description

Entheon Biomedical Corp. operates as a biotechnology research and drug development company. It engages in developing and commercializing various N,N-dimethyltryptamine based psychedelic therapeutic products for treating addiction and substance use...

Read more

Entheon Biomedical Corp. operates as a biotechnology research and drug development company. It engages in developing and commercializing various N,N-dimethyltryptamine based psychedelic therapeutic products for treating addiction and substance use...

Entheon Biomedical Financial Statement Overview

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Entheon Biomedical Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.06
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ENBI.X, the sentiment is Negative. The current price of 0.06 is below the 20-day moving average (MA) of 0.06, below the 50-day MA of 0.06, and below the 200-day MA of 0.08, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 42.00 is Neutral, neither overbought nor oversold. The STOCH value of 0.00 is undefined, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:ENBI.X.

Entheon Biomedical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BETR	49 Neutral	C$55.04M	-32.00	19.88%	―	―	15.07%
ENBI.X	41 Neutral	C$831.54K	-4.27	-78.74%	―	―	―